MRK Stock Analysis: Buy, Sell, or Hold?
MRK - Merck & Co., Inc.
$129.56
4.19 (3.34%)
▲
5d:
+3.28%
30d:
+12.03%
90d:
+7.22%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
30d
Smart Money Distribution
None View Scanner →
Strength: 9.0/10
Get Alerted When MRK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called MRK this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MRK shows positive signals but monitor for confirmation. Market pricing in 2.0% growth. Moderate conviction.
💡 BUY OPPORTUNITY: MRK shows positive signals but monitor for confirmation. Market pricing in 2.0% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$236.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$147.08
11.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MRK is currently trading at $129.56, which is considered extended relative to its 30-day fair value range of $115.52 to $124.86. The stock's valuation (Forward PE: 13.5) is in line with its historical norms (12.7). At these levels, the market is pricing in 2.0% annual earnings growth.
Technical Outlook: Technically, MRK is in a uptrend. The price is approaching resistance at $130.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: MRK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MRK is in a uptrend. The price is approaching resistance at $130.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: MRK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$115.52 -
$124.86
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- NEUTRAL: Near Wall St target ($130.78)
- BULLISH: Expecting earnings turnaround to 2.0% growth with 4.9% revenue growth
Trading Range Analysis
30-Day Trading Range
$115.52 -
$124.86
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$111.57
Resistance Level
$130.29
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.53
Wall Street Target
$130.78
(+0.9%)
Revenue Growth (YoY)
4.9%
Earnings Growth (YoY)
-19.3%
Profit Margin
13.6%
Valuation Premium vs History
+2.0% premium
PE vs Historical
13.5 vs 12.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.0%
(market-implied from PE analysis)
1-Year Target
$132.15
(+2%)
2-Year Target
$134.79
(+4%)
3-Year Target
$137.49
(+6%)
3-Yr Target (if PE normalizes)
(PE: 14→13)
PE COMPRESSION
$129.08
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 216.6%)
$704.05
(+443%)
Base:
(SPY PE: 13.5, Growth: 216.6%)
$437.26
(+238%)
Bear:
(PE: 11.5, Growth: 216.6%)
$371.68
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (35x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 35.32 | Current EPS (TTM): $3.55
Bull Case
$275.81
(+113%)
Analyst growth 100.0%, PE expands to 38.9
Base Case
$250.74
(+94%)
Market implied 100.0%, PE stable at 35.3
Bear Case
$85.25
(-34%)
Severe decline -20.0%, PE contracts to 30.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 04, 2026 11:14 AM ET
Data refreshes hourly during market hours. Next update: 12:14 PM
Data refreshes hourly during market hours. Next update: 12:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRK showing a specific setup today?
Insider Activity (6 Months)
2
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-03-10
Chirfi Guindo
SELL
10000 shares
2026-02-09
Jennifer Zachary
SELL
121573 shares
2026-02-09
Featured in Portfolios
MRK is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 67 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 60 HOLD |
Advanced MRK Option Strategies
Professional options setups generated by AI based on today's MRK price and gamma walls.
